

CLEC12A/MICL/CLL-1
Catalog # PVGS1821**Specification**

CLEC12A/MICL/CLL-1 - Product Information

Primary Accession [Q5OGZ9-2](#)
Species
Human

Sequence
His65-Ala265

Purity
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC

Endotoxin Level
Less than 1EU per µg by the LAL method.

Biological Activity
Immobilized CLEC12A/MICL/CLL-1 hFc Chimera, Human (Cat.No.: Z03958) at 0.5 µg/ml (100 µl/Well) on the plate can bind Biotinylated Anti-CLEC12A Antibody, hFc Tag

Expression System
HEK293

Theoretical Molecular Weight
50.9 kDa

Formulation **Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4).**

Reconstitution
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O more than 100 µg/ml.

Storage & Stability
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

CLEC12A/MICL/CLL-1 - Additional Information

Target Background
CLEC12A, also known as CLL-1 is inhibitory C-type lectin-like receptor with ITIM motif. It can associate with signaling phosphatases SHP-1 and SHP-2. CLEC12A is a potential target due to its high expression in acute myeloid leukemia (AML) cells. And there are various therapeutic approaches using CLEC12A as a target for AML, such as CD3/ CLEC12A antibody. It can recruit unstimulated primary T cells against cancer cells with CLL-1 on the surface.

CLEC12A/MICL/CLL-1 - Protein Information

CLEC12A/MICL/CLL-1 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

CLEC12A/MICL/CLL-1 - Images